Pertussis Vaccine Market Is Forecasted To Grow Steadily And Reach USD $6.82 Billion By 2030

 The Business Research Company’s 2026 market reports incorporate enhanced features, including market attractiveness scoring and analysis, total addressable market evaluation, a company scoring matrix, an interactive Excel data dashboard, refined supply chain analysis, insights on emerging startups, and overviews of key products, all aimed at improving the depth, usability, and strategic relevance of the insights delivered.

 
 What Is The Anticipated Market Value Of The Pertussis Vaccine Market Over The Forecast Period?
 The pertussis vaccine market size has grown steadily in recent years. It will grow from $5.65 billion in 2025 to $5.82 billion in 2026 at a compound annual growth rate (CAGR) of 2.9%. The growth in the historic period can be attributed to high childhood immunization coverage, government-led national vaccination programs, historical outbreaks of whooping cough, inclusion of pertussis vaccine in routine immunization schedules, availability of whole-cell vaccines.
 
 The pertussis vaccine market size is expected to see steady growth in the next few years. It will grow to $6.82 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to rising awareness of adult pertussis vaccination, increasing maternal immunization recommendations, advancements in vaccine safety and efficacy, expansion of healthcare access in emerging economies, growth in combination vaccine development. Major trends in the forecast period include rising adoption of acellular pertussis vaccines, increasing focus on booster immunization programs, expansion of combination vaccines including pertussis, growing adult and maternal pertussis vaccination, strengthening government immunization initiatives.
 
 Download Your Free Report Sample:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=13023&type=smp
 
 Which Growth Factors Are Influencing The Expansion Of The Pertussis Vaccine Market? 
 Rising childbirth rates are driving the growth of the pertussis vaccine market going forward. Childbirth is the term for the act of giving birth to a child. It is the culmination of pregnancy, during which the fetus develops in the mother’s uterus and marks the beginning of a new life outside the womb. The pertussis vaccine is primarily used for children because it helps protect them from whooping cough and other severe and potentially deadly diseases. For instance, in January 2023, according to a report published by the Centers for Disease Control and Prevention, a US-based national public health organization, the United States witnessed a 1% increase in registered births, totaling 3,664,292, compared to 2022. Therefore, the rising childbirth rates are driving the growth of the pertussis vaccine market.
 
 Who Are the Key Players Driving the Pertussis Vaccine Market?
 The pertussis vaccine market covered in this report is segmented — 
 
 1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine
 2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine
 3) By Application: Children, Adults, Infants
 4) By End-User: Vaccination Centers, Hospitals, Clinics
 
 Subsegments:
 1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP
 2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine
 
 What Market Trends Should Companies Track In The Pertussis Vaccine Market?
 Major companies operating in the pertussis vaccine market are focusing on developing advanced immunization solutions and securing regulatory approvals to enhance maternal and infant protection against whooping cough. These efforts aim to improve vaccine accessibility, expand recommended use in pregnancy, and reduce pertussis-related morbidity among newborns. For instance, in January 2023, Sanofi S.A., a France-based biopharmaceutical company received U.S. FDA approval for the expanded use of its Adacel (Tdap) vaccine during the third trimester of pregnancy, enabling maternal immunization to help protect infants younger than two months who are at highest risk of severe pertussis infection. This approval allows healthcare providers to actively immunize pregnant individuals, ensuring that protective antibodies are passed to the newborn before birth. As a result, infants gain early-life protection against pertussis, bridging the immunity gap until they can receive their own vaccinations. 
 
 How Are Different Segments Organized Within The Pertussis Vaccine Market?
 The pertussis vaccine market covered in this report is segmented — 
 
 1) By Product Type: DTaP (Diphtheria, Tetanus and Acellular Pertussis) Vaccine, Tdap (Tetanus, Diphtheria and Pertussis) Vaccine
 2) By Vaccine Type: Whole-Cell Vaccine, Acellular Vaccine
 3) By Application: Children, Adults, Infants
 4) By End-User: Vaccination Centers, Hospitals, Clinics
 
 Subsegments:
 1) By DTaP (Diphtheria, Tetanus, And Acellular Pertussis) Vaccine: Pediatric DTaP Vaccine, Combination Vaccines With DTaP
 2) By Tdap (Tetanus, Diphtheria, And Pertussis) Vaccine: Adolescent Tdap Vaccine, Adult Tdap Vaccine
 
 Explore the Complete Pertussis Vaccine Market Report:
 https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report
 
 Which Regions Are Projected To Grow At The Highest Rate In The Pertussis Vaccine Market?
 https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report
 
 #Contact Us:#
 
 The Business Research Company: https://thebusinessresearchcompany.com/ 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 Email: marketing@tbrc.info
 
 #Follow Us On:#
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company